Frank Glavin, CEO
Frank Glavin is CEO of Orphan Technologies, a Neopharm company focused on the research and development of innovative therapies. In addition, he is the Vice President of Neovii Biotech North America and a member of the Neovii Executive Management Committee. He oversees the group’s strategy, clinical and commercial development, and operations. Mr. Glavin joined the company in 2009 and brings 15+ years of drug and commercial development experience in both public and private companies to Neovii. Previously he was Director of Therapeutics at CombinatoRx where he spearheaded translational drug development advancing 2 products from the lab to the clinic. Prior to that, Mr. Glavin developed processes and frameworks to plan, execute, and measure the portfolio of strategic initiatives as a member of the Serono Strategic Planning team and was a Life Science Management Consultant developing new-business incubation, in-licensing and acquisition, and franchise development strategies for global pharmaceutical and health care clients. Mr. Glavin has a B.S. in Human Physiology from Boston University as well as an MBA from the Johnson Graduate School of Management at Cornell University.
Márcia Sellos-Moura, PhD, Vice President, Head of Program and Portfolio Management
Márcia Sellos-Moura, PhD is Vice President and Head of Program and Portfolio Management. She joined Orphan Technologies in January 2016 as Associate Vice President and Program Executive. Márcia brings over 20 years of global R&D and program management experience, with line and cross-functional leadership, with emphasis in preclinical and clinical development, bioanalytical and translational sciences. Previously, Márcia held a variety of positions of increasing responsibility at Shire and Transkaryotic Therapies and was an integral contributor to the approval of four products and to the development of greater than 20 candidates across their rare disease portfolios. She has authored multiple manuscripts and has been granted several patents throughout her academic and industry career. Márcia received her PhD in Biochemistry, Cell and Molecular Biology and her B.A. in Biochemistry and Chemistry from Cornell University, and a Graduate degree in Biopharmaceutical International Regulatory Affairs from Northeastern University
Erez Bublil, PhD, Vice President, Research and Development
Dr. Erez Bublil is Orphan Technologies’ Vice President of Research and Development. In his capacity, he initiates and overseas the design, development, execution and implementation of research and development projects and executes both basic and applied research to build, support and extend Orphan Technologies’ innovative portfolio. Dr. Bublil Joined Orphan Technologies in 2014, and brings 20 years of research experience in the academia. He has authored manuscripts and reviews in peer reviewed journals, authored book chapters, and has several patents to his name. Before joining Orphan Technologies, Dr. Bublil served as a scientist at the University of Colorado Denver, where he was instrumental to the research on Orphan’s lead drug candidate, OT-58. Dr. Bublil earned his B.Sc. (Magna Cum Laude) and M.Sc. (Summa Cum Laude) from Tel-Aviv University, focusing on cancer therapeutics. He earned his PhD in Cell Research and immunology from Tel-Aviv University focusing on rational design of HIV vaccines. His postdoc studies were carried out at the Weizmann Institute of Science at the prestigious laboratory of Prof. Yosef Yarden, where he focused on signal transduction in cancer, and development of anti-cancer therapeutics.
Patrick Horn, MD, PhD, Senior Vice President, Medical and Clinical Development
Patrick Horn leads the clinical program for OT-58. He has approximately 20 years of drug development experience in both large and small companies. Most recently he was Chief Medical Officer at Tetraphase Pharmaceuticals where he oversaw the clinical development for all antibiotic candidates, including the program leading to the New Drug Application for eravacycline. Prior to that, Pat lead the clinical program at Dyax that resulted in the approval of Kalbitor for the treatment of Hereditary Angioedema. Earlier he was the head of Clinical Pharmacology at Abbott Laboratories. Pat received both his MD and PhD from the University of Chicago and completed a Pediatric Residency at Boston Children’s Hospital. Prior to transitioning to industry, Pat was a practicing Pediatrician in Chicago for almost 20 years
Alfred Doucette, Chief Financial Officer
With more than 20 years of experience in the pharmaceutical industry, Mr. Doucette joined the company in 2018. Previously, he held senior international finance and commercial positions in Wyeth Pharmaceuticals, later acquired by Pfizer Inc. His most recent role was Regional Commercial Director SEE/Turkey/Greece/Israel for Pfizer’s Consumer Healthcare business unit. Mr. Doucette holds a degree in business administration from Vienna University of Economics and Business.